| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2023 | 15706 | 1.940 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2022 | 839 | 1.490 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2022 | 485 | 1.470 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2019 | 608 | 1.370 |
Why?
|
| Medication Adherence | 4 | 2023 | 498 | 1.240 |
Why?
|
| Oncogene Proteins | 2 | 2021 | 356 | 1.230 |
Why?
|
| Receptor, ErbB-2 | 9 | 2023 | 2519 | 1.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2015 | 748 | 0.970 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2022 | 6 | 0.840 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 42 | 0.820 |
Why?
|
| Receptors, Estrogen | 8 | 2020 | 2084 | 0.770 |
Why?
|
| Prescription Drugs | 2 | 2019 | 64 | 0.740 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 5187 | 0.730 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2005 | 79 | 0.710 |
Why?
|
| Estrogen Receptor alpha | 2 | 2022 | 701 | 0.690 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 229 | 0.660 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 521 | 0.580 |
Why?
|
| Estrogen Antagonists | 2 | 2018 | 183 | 0.530 |
Why?
|
| Quinolines | 1 | 2019 | 384 | 0.530 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 471 | 0.520 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 66 | 0.510 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2005 | 142 | 0.510 |
Why?
|
| Mucositis | 1 | 2015 | 148 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10067 | 0.490 |
Why?
|
| Cancer Survivors | 2 | 2018 | 650 | 0.480 |
Why?
|
| Tamoxifen | 6 | 2022 | 875 | 0.480 |
Why?
|
| Glutamine | 1 | 2015 | 300 | 0.470 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 803 | 0.470 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 7 | 0.460 |
Why?
|
| Thiazolidinediones | 2 | 2005 | 148 | 0.460 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 14300 | 0.460 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 305 | 0.440 |
Why?
|
| Cytotoxins | 1 | 2012 | 66 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2013 | 266 | 0.420 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2013 | 216 | 0.420 |
Why?
|
| Ketones | 1 | 2012 | 54 | 0.410 |
Why?
|
| Furans | 1 | 2012 | 106 | 0.410 |
Why?
|
| RANK Ligand | 1 | 2012 | 119 | 0.390 |
Why?
|
| Drug Eruptions | 1 | 2013 | 257 | 0.380 |
Why?
|
| Female | 33 | 2023 | 142232 | 0.370 |
Why?
|
| Quinazolines | 3 | 2015 | 924 | 0.360 |
Why?
|
| Heterografts | 4 | 2022 | 734 | 0.350 |
Why?
|
| Estradiol | 4 | 2022 | 747 | 0.330 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 65 | 0.320 |
Why?
|
| Epothilones | 1 | 2008 | 54 | 0.320 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 14588 | 0.320 |
Why?
|
| Palliative Care | 1 | 2019 | 2032 | 0.310 |
Why?
|
| Humans | 39 | 2023 | 262185 | 0.300 |
Why?
|
| Obesity | 3 | 2023 | 2893 | 0.300 |
Why?
|
| Microtubules | 1 | 2008 | 271 | 0.290 |
Why?
|
| Estrogens | 3 | 2022 | 748 | 0.290 |
Why?
|
| Cell Membrane | 3 | 2005 | 855 | 0.280 |
Why?
|
| Postmenopause | 3 | 2023 | 377 | 0.270 |
Why?
|
| Dopamine | 2 | 2004 | 313 | 0.270 |
Why?
|
| Cell Proliferation | 5 | 2022 | 7241 | 0.260 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2005 | 44 | 0.260 |
Why?
|
| Mice | 11 | 2022 | 34407 | 0.250 |
Why?
|
| Animals | 15 | 2022 | 59506 | 0.250 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2004 | 40 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2020 | 1556 | 0.240 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2004 | 132 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15874 | 0.220 |
Why?
|
| Transplantation, Autologous | 3 | 2013 | 1922 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 198 | 0.210 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2021 | 35 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 6558 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3891 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 1303 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 318 | 0.190 |
Why?
|
| Medicare | 2 | 2023 | 896 | 0.190 |
Why?
|
| G1 Phase | 1 | 2021 | 285 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 278 | 0.180 |
Why?
|
| Hyaluronan Receptors | 2 | 2018 | 249 | 0.180 |
Why?
|
| Polypharmacy | 1 | 2019 | 57 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2578 | 0.170 |
Why?
|
| Signal Transduction | 7 | 2021 | 11970 | 0.170 |
Why?
|
| Cinnamates | 1 | 2018 | 27 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 11575 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 4382 | 0.170 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 48 | 0.170 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 185 | 0.160 |
Why?
|
| Metformin | 1 | 2022 | 378 | 0.160 |
Why?
|
| Aged | 9 | 2023 | 70323 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 2638 | 0.160 |
Why?
|
| Keratins | 1 | 2019 | 330 | 0.160 |
Why?
|
| Neoplasms | 2 | 2015 | 15201 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2019 | 32986 | 0.150 |
Why?
|
| Middle Aged | 10 | 2020 | 86445 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 342 | 0.150 |
Why?
|
| Purines | 1 | 2018 | 274 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 218 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 8891 | 0.150 |
Why?
|
| Transcriptome | 2 | 2016 | 1859 | 0.150 |
Why?
|
| Cell Separation | 1 | 2019 | 607 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2018 | 212 | 0.150 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 1388 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2023 | 38007 | 0.140 |
Why?
|
| Mice, SCID | 2 | 2019 | 1870 | 0.140 |
Why?
|
| Atrophic Vaginitis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Adult | 8 | 2020 | 78082 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 2214 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 354 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 323 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 64 | 0.140 |
Why?
|
| Rats | 4 | 2008 | 6109 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2021 | 4317 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 29997 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 5122 | 0.130 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1517 | 0.130 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 35 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 4980 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 244 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7217 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1079 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2021 | 1030 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2300 | 0.120 |
Why?
|
| Rats, Zucker | 2 | 2005 | 60 | 0.120 |
Why?
|
| Neutropenia | 2 | 2009 | 967 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1229 | 0.120 |
Why?
|
| Colforsin | 2 | 2004 | 59 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3830 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 520 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1567 | 0.120 |
Why?
|
| Mastectomy | 1 | 2020 | 1538 | 0.120 |
Why?
|
| Pain Management | 1 | 2019 | 670 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 78 | 0.110 |
Why?
|
| Breast | 1 | 2020 | 1350 | 0.110 |
Why?
|
| Blood Component Removal | 1 | 2013 | 122 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 2844 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1011 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 13672 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 929 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1360 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 17606 | 0.100 |
Why?
|
| Endocrine System | 1 | 2011 | 36 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 970 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 68 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2478 | 0.100 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 112 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2018 | 1817 | 0.100 |
Why?
|
| Male | 9 | 2020 | 123269 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 704 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2333 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 2326 | 0.090 |
Why?
|
| Leukopoiesis | 1 | 2009 | 6 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 2187 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2005 | 1242 | 0.090 |
Why?
|
| Filgrastim | 1 | 2009 | 191 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 1494 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 6038 | 0.090 |
Why?
|
| Ketoglutaric Acids | 1 | 2009 | 38 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1372 | 0.090 |
Why?
|
| California | 1 | 2009 | 208 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2009 | 44 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 1878 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2009 | 211 | 0.090 |
Why?
|
| Depression | 1 | 2019 | 1715 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 622 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2005 | 730 | 0.080 |
Why?
|
| United States | 2 | 2023 | 15561 | 0.080 |
Why?
|
| Insulin | 2 | 2005 | 1447 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 2234 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 554 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3002 | 0.080 |
Why?
|
| Young Adult | 3 | 2019 | 21473 | 0.080 |
Why?
|
| Biological Assay | 1 | 2009 | 177 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2632 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 1153 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 566 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 935 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2011 | 2078 | 0.070 |
Why?
|
| CD24 Antigen | 2 | 2018 | 85 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 553 | 0.070 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2005 | 2 | 0.070 |
Why?
|
| Recurrence | 1 | 2013 | 4765 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2005 | 58 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2004 | 52 | 0.060 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2004 | 38 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 39 | 0.060 |
Why?
|
| Microvilli | 1 | 2004 | 83 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 393 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 52 | 0.060 |
Why?
|
| Cytokines | 1 | 2013 | 2812 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2004 | 328 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 62 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 6892 | 0.060 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2004 | 36 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 236 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2915 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 1098 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1448 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 21745 | 0.060 |
Why?
|
| Benzazepines | 1 | 2004 | 109 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2004 | 135 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 591 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 143 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2004 | 358 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 12969 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 12915 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 3752 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 322 | 0.050 |
Why?
|
| Length of Stay | 1 | 2009 | 1929 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 5154 | 0.050 |
Why?
|
| Sodium | 1 | 2004 | 353 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 735 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2815 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3262 | 0.050 |
Why?
|
| Body Weight | 1 | 2005 | 1292 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2020 | 92 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 2237 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 3081 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10355 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 2073 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 2421 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 15185 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1465 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 132 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2004 | 3537 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12236 | 0.040 |
Why?
|
| Apoptosis | 1 | 2012 | 7608 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 246 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 697 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2005 | 4813 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 12 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4563 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 79 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 6696 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 14902 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 2323 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2013 | 177 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2394 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1316 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 802 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 6105 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2013 | 246 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 669 | 0.030 |
Why?
|
| Stem Cells | 1 | 2018 | 1210 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 1396 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 368 | 0.020 |
Why?
|
| Terfenadine | 1 | 2010 | 2 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5385 | 0.020 |
Why?
|
| Quinidine | 1 | 2010 | 16 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 1035 | 0.020 |
Why?
|
| Propanolamines | 1 | 2010 | 43 | 0.020 |
Why?
|
| Digoxin | 1 | 2010 | 64 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2297 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 906 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 373 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 10 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2009 | 22 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2009 | 81 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2009 | 62 | 0.020 |
Why?
|
| Succinic Acid | 1 | 2009 | 23 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 50 | 0.020 |
Why?
|
| Adolescent | 1 | 2009 | 31247 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 3047 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 254 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 2671 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 10009 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 552 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1758 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1412 | 0.020 |
Why?
|
| Hydrazines | 1 | 2009 | 208 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 384 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3563 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 2040 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 1998 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9186 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 4578 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 5052 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 1477 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 4347 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 4108 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2009 | 1661 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 6265 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 4555 | 0.010 |
Why?
|